THE JENEX CORPORATION
SUITE 207, 940 SHELDON COURT
BURLINGTON, ONTARIO
L7L 5K6 PH: (905) 632 - 3830
FAX: (905) 632 - 3774

ALBERTA SECURITIES COMMISSION
MARKET SURVEILLANCE/CONTINUOUS DISCLOSURE
19th Floor, 10025 Jasper Avenue
Edmonton, Alberta
T5K 3Z5
Attention: Executive Director

THE BRITISH COLUMBIA SECURITIES COMMISSION
Suite 200, 865 Hornby Street
Vancouver, British Columbia
V6Z 2H4
Attention: Continuous Disclosure Department

Dear Sirs:

Re: THE JENEX CORPORATION - MATERIAL CHANGE REPORT UNDER SECTION 146 of the SECURITIES ACT (ALBERTA), SECTION 75(2) of the SECURITIES ACT (ONTARIO), and SECTION 67(1) OF THE SECURITIES ACT (BRITISH COLUMBIA)

This letter is intended as a statement setting forth certain matters that may be a material change in the affairs of The Jenex Corporation (the "Corporation"). For convenience, this letter is itemized in the same manner as Form 27 of the *Securities Act* (Alberta), Form 27 of the *Securities Act* (Ontario), and Form 27 of the Securities Act (British Columbia). Concurrent with this filing, this letter is being filed with the Canadian Venture Exchange Inc., being the only Exchange on which the Corporation's shares are currently listed.

Item 1 - Reporting Issuer

The Jenex Corporation
Suite 207, 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Ph: (905) 632 - 3830
Fax: (905) 632 - 3774

Item 2 - Date of Material Change

The material change occurred on March 11, 2002

Item 3 - Publication of Material Change/Press Release

A Press Release was issued on or about March 11, 2002

Item 4 - Summary of Material Change

The Corporation announced that it proposes to raise up to $3,000,000 by way of a private placement through the issue of up to 2,000,000 common shares at $1.50 per common share. Proceeds from the financing will be used to secure clearance to market in Europe and Australia and to finalize its North American marketing program. The proposed private placement is subject to customary regulatory approval and all common shares issued will be subject to a four month hold period under applicable securities legislation.

Item 5 - Full Description of Material Changes

See the attached Press Release.

Item 6 - Reliance on Section 146(4) of the Securities Act (Alberta) or Section 75(3) of the Securities Act (Ontario) and Section 67(1) of the Securities Act (British Columbia)

Not applicable

Item 7 - Omitted Information

Not applicable

Item 8 - Senior Officer

The name of a Senior Officer of the Corporation who is knowledgeable about the material change and who can be contacted by the Commission is:

Mr. Michael A. Jenkins
Tel: (905) 632 - 3830

Item 9 - Statement of a Senior Officer

The foregoing accurately discloses the material change referred to in this report.

DATED at Burlington, Ontario, this 12th day of March, 2002.

THE JENEX CORPORATION

Per: (Signed) "Michael A. Jenkins"
Michael A. Jenkins - President

THE JENEX CORPORATION
"Prevention is the Solution"

Press Release
PRIVATE PLACEMENT

FOR IMMEDIATE RELEASE
March 11, 2002
Burlington, Ontario

THE JENEX CORPORATION (CDNX - "Jen" or the "Corporation"), the first company to receive approval from a significant regulatory body to make the **prevention** claim for cold sores, announces that it proposes to raise up to $3,000,000 by way of a private placement through the issue of up to 2,000,000 common shares at $1.50 per common share. Proceeds from the financing will be used to secure clearance to market in Europe and Australia and to finalize its North American marketing program. The proposed private placement is subject to customary regulatory approval and all common shares issued will be subject to a four month hold period under applicable securities legislation.

About The Jenex Corporation

Headquartered in Burlington, Ontario, the Corporation has developed and patented a thermal therapeutic device for the prevention of cold sores. Patents in fifteen countries, including the United States, Canada, Australia, and the E.E.C protect the technology. Clearance from regulatory, Therapeutic Products Programme (TPP), in Canada has been received to market their thermal therapy device, over-the-counter (OTC) with the claim *"For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks"*. A medical device license has been issued by TPP, in accordance with Medical Device Regulations. Jenex is the first company to receive clearance to market from a significant regulatory body to make the **prevention** claim for cold sores.

The Corporation is currently seeking clearance from FDA to make a similar marketing claim in the United States. Management of the Corporation expects a response from the FDA in the 2nd quarter of 2002.

Jenex is now seeking a strategic corporate partner to license and commercialize their thermal therapy technology. Several Multi-National Companies have signed Confidentiality Agreements and are in various stages of due diligence.

The HSV-1 virus that causes cold sores, is endemic in North America, and is estimated to affect 80% of the population. As the only product clinically proven to prevent the outbreak of cold sores, the Corporation's thermal therapy product has the potential to dominate a large and underdeveloped market.

"Prevention is the Solution"

For further information, see www.jenexcorp.com or contact:

Michael A. Jenkins, President
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632–3774
Email: Jenex@sprint.ca

The Canadian Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.